131 results on '"Frouni, Imane"'
Search Results
2. Positive allosteric mGluR2 modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
3. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain
4. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
5. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
6. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain
7. Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
8. Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat
9. Pharmacotherapy of Psychosis in Parkinson’s Disease
10. Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset
11. Metabotropic glutamate receptors in Parkinson's disease
12. Cognition and serotonin in Parkinson's disease
13. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
14. Effect of the mGlu2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset.
15. Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism.
16. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.
17. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset
18. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset
19. Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose
20. Pharmacokinetic profile of the selective [5-HT.sub.3] receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat
21. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset
22. Pharmacotherapy of Psychosis in Parkinson’s Disease
23. Activation of mGlu2/3receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
24. The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset.
25. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
26. 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
27. Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
28. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset
29. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
30. Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
31. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
32. Classic animal models of Parkinson’s disease: a historical perspective
33. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
34. Development and validation of a sensitive HPLC-HESI-MS/MS method for quantitative determination of bitopertin in rat and marmoset plasma
35. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
36. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic
37. Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat.
38. Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials
39. Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain
40. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
41. Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
42. Development and validation of a sensitive HPLC-HESI-MS/MS method for quantitative determination of bitopertin in rat and marmoset plasma
43. Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
44. The highly selective mGlu 2 receptor positive allosteric modulator LY‐487,379 alleviates l ‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease
45. Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
46. Effet de l’activation du récepteur mGluR2 par LY-354,740 sur les dyskinésies chez le modèle parkinsonien de rat lésé à la 6-hydroxydopamine
47. 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
48. Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
49. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
50. The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.